32 results about "Human coagulation factor VII" patented technology

The present invention relates to human coagulation Factor VII polypeptides, as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions comprising Factor VII polypeptides, uses and methods of treatment; and any additional inventive features related thereto.

The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

The present invention relates to novel human coagulation Factor VII / VIIa proteins having coagulant potential / activity as well as pharmaceutical compositions comprising the proteins, uses thereof, and methods of treatment therewith. In particular, the present invention relates to novel, semi synthetic analogues of human coagulation Factor VII and VIIa (FVII and FVIIa) as well as to a method of their production.

The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmaceutical compositions, uses and methods of treatment.

The invention concerns novel coagulation factor VII variants, wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs; with the proviso that the variant is not FVII(Ala305). The invention further concerns nucleic acids encoding the Factor VII variants; vectors and cells comprising the nucleic acid; methods for producing the variants; pharmaceutical compositions comprising a Factor VII variant wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs; use of the variants for producing a medicament for treatment or prophylaxis of bleeding disorders or enhancement of the coagulation system; and methods of treatment.

The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

The invention concerns nucleic acids encoding coagulation Factor VII variants in which the Leu residue in position 305 has been replaced by another amino acid residue. The invention further concerns the expression of such nucleic acids resulting in a Factor VII variant having increased biological activity.

The invention discloses a method for purifying a human coagulation factor VII from human plasma. The method comprises the following steps: (1) removing cold gel plasma, (2) performing anion exchange chromatography for the first time, (3) filtering the eluent, and adjusting the conductivity and pH value of the product, and (4) carrying out ion exchange chromatography for the second time. Accordingto the method, the human coagulation factor VII can be separated from the cold-gel-free plasma by adopting sodium glutamate as an eluent through first ion exchange chromatography, and the human coagulation factor VII can be further purified through two times of chromatography, so that the utilization rate of the plasma is greatly improved, and the human coagulation factor VII can achieve relatively high specific activity.

The present invention relates to novel human coagulation Factor VII polypeptides, Factor VII derivatives as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

The invention provides a host cell containing a vector for expressing a functional recombinant human coagulation factor VII and a high-level expression method of the functional recombinant human coagulation factor VII, and aims at establishing an expression vector containing F VII, GGCX and VKORC1 recombinant nucleic acids and improving the g-carboxylation modification of the recombinant F VII by virtue of coordinated expression of the GGCX and the VKORC1. The host cell contains the F VII recombinant nucleic acid (human coagulation factor VII), depending on which the vitamin K is coded, a VKORC1 (mouse vitamin K epoxide reductase complex subunit 1) recombinant nucleic acid and a GGCX (mouse g glutamyl carboxylase) recombinant nucleic acid, as well as an insulator (4X) recombinant nucleic acid; the high-level expression method of the functional recombinant human coagulation factor VII comprises the steps of establishing an expression vector, mediating the expression vector into a DHFR deficient CHO animal cell by use of a lipidosome method and screening out positive clones by virtue of a DMEM culture medium, performing serum-free acclimation and culture on the host cell strain, purifying the h FVII recombinant protein by virtue of nickel ion affinity chromatography and performing SDS-PAGE and Westernblot detection, and finally, determining the procoagulant activity of the FVII recombinant protein according to the prothrombin time (PT).

A method for the mass production of human coagulation factor VII. The method includes a) providing an expression vector carrying i) a dihydrofolate reductase promoter devoid of one or more CCGCC repeat sequences from the GC-rich region thereof and a dihydrofolate reductase (DHFR) gene operably linked thereto and ii) a cytomegalovirus (CMV) promoter and a human coagulation factor VII gene operably linked thereto; b) obtaining a transformed a host cell line containing the expression vector; and c) culturing the transfected host cell in the presence of a dihydrofolate reductase inhibitor to select cells which express human coagulation factor VII with high efficiency; and d) adding sodium butyrate to the selected host cells.

In the invention, the minimum inhibitory concentrations of human coagulation factor light-chain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity and the inhibiting effect of the human coagulation factor light-chain proteins against different Gram-negative bacteria is detected with the in vivo antibacterial activity. It has been shown that human coagulation factor light-chain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by mass spectrometry and silver staining that human coagulation factor light-chain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia. The human coagulation factor light-chain proteins are light chain proteins of human coagulation factors VII, IX, and X, as well as a protein having homology of more than 50% thereof.

A method for the mass production of human coagulation Factor VII. The method includes a) providing an expression vector carrying i) a dihydrofolate reductase promoter devoid of one or more CCGCC repeat sequences from the GC-rich region thereof and a dihydrofolate reductase (DHFR) gene operably linked thereto and ii) a cytomegalovirus (CMV) promoter and a human coagulation Factor VII gene operably linked thereto; b) obtaining a transformed host cell line containing the expression vector; and c) culturing the transfected host cell in the presence of a dihydrofolate reductase inhibitor to select cells which express human coagulation Factor VII with high efficiency; and d) adding sodium butyrate to the selected host cells.

The invention provides a method for producing a recombinant human coagulation factor VII by using a rabbit mammary gland reactor platform. CDNA (Complementary deoxyribonucleic acid) of the recombinant human coagulation factor VII is guided or integrated to a chromosome gene of a rabbit, and the obtained transgenic rabbit expresses recombinant human coagulation factor VII protein in a mammary gland reactor. The transgenic rabbit has relatively high recombinant human coagulation factor VII protein expression level in the mammary gland reactor, the protein activity is good, and the production cost is reduced.

The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

The invention relates to a hybridomas cell strain secreting anti-human coagulation factor VII polyclonal antibody and a preparation method thereof. The preparation method comprises using a conjugate obtaining by performing coupling on bovine serum albumin (BSA) and human coagulation factor VII as an antigen for immunizing Balb / c mouse, getting spleen cell of the mouse and performing cell fusion with SP2 / 0 myeloma cell, performing selective culture by using HAT medium, selecting fusion cell of the mouse spleen cell and the mouse myeloma cell SP2 / 0, and finally identifying the hybridomas cell strain secreting anti-human coagulation factor VII polyclonal antibody through ELISA. The prepared hybridomas cell strain is preserved in China Center for Type Culture Collection with the preservation number of CCTCC C2015195.